Author

F. Curreli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2

Frequent Co-Authors

S. Ahmed· 3 shared A. Drelich· 2 shared A. K. Debnath· 2 shared C. D. Hillyer· 2 shared S. M. B. Victor· 2 shared A. Altieri· 1 shared A. Debnath· 1 shared A. Kurkin· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

S. Ahmed

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery of highly potent small molecule pan-coronavirus fusion inhibitors

F. Curreli, K. Chau, T.-T. Tran, I. Nicolau, S. Ahmed, P. Das, C. D. Hillyer, M. Premenko-Lanier, A. K. Debnath

This paper discovers and characterizes NBCoV63, a potent small molecule inhibitor effective against multiple SARS-CoV-2 variants and other coronaviruses.

bioRxiv · Jan 17, 2023Pharmacology & Toxicology

Discovery of highly potent pancoronavirus fusion inhibitors that also effectively inhibit COVID-19 variants from the UK (Alpha), South Africa (Beta), and India (Delta)

F. Curreli, S. Ahmed, S. M. B. Victor, A. Drelich, S. S. Panda, A. Altieri, A. Kurkin, C.-T. Tseng, C. Hillyer, A. Debnath

The paper identifies potent small molecules that inhibit multiple coronaviruses, including SARS-CoV-2 variants, with high selectivity and in vivo efficacy.

bioRxiv · Sep 3, 2021Pharmacology & Toxicology

Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro

F. Curreli, S. M. B. Victor, S. Ahmed, A. Drelich, X. Tong, C.-T. K. Tseng, C. D. Hillyer, A. K. Debnath

This study designs stapled peptides based on the ACE2 helix to inhibit SARS-CoV-2 infection, showing potent antiviral activity with no cytotoxicity.

bioRxiv · Aug 25, 2020Pharmacology & Toxicology